POST Online Media Lite Edition


Ichnos Sciences appoints Sonia Quaratino to board

Christian Fernsby |
New York, N.Y., USA - Ichnos Sciences Inc., a biotechnology company, announced that Sonia Quaratino has been appointed as an independent member of its board of directors.

Article continues below

Dr. Quaratino has over twenty-five years of experience in immunology research, clinical development at biotechnology and pharmaceutical companies, has served on multiple boards, and overseen research programs at leading academic institutions.

Most recently, Dr. Quaratino was Chief Medical Officer for Kymab, an innovative biotech in immunology and immuno-oncology that was acquired by Sanofi in April 2021.

She has been Chair of the Scientific and Clinical Advisory Board for STipe Therapeutics since May of 2020 and a non-executive director for TargoVax ASA since March of 2021.

Previously, she held roles as Global Clinical Program Leader in Translational Clinical Oncology at Novartis, Senior Medical Director and Immunology Advisor at Merck Serono, and was Professor of Immunology at the University of Southampton.

Dr. Quaratino received her Medical Degree and Doctorate in Hematology-Oncology from the University of Palermo, and her Ph.D. in Immunology from Imperial College London.

In addition to her professional and academic roles, Dr. Quaratino is a member of the General Medical Council in the United Kingdom, the American Society for Clinical Oncology, and the American Association for Cancer Research.